Novo Nordisk$NVO
16 research articles
By following, you request company-alert emails. Manage or stop them anytime in your account. Privacy.
Research Articles
$NVO: Continued execution
Novo Nordisk ($NVO) • By TQI Capital • 2026-11-11
The Weekly Screener - November, 09: Halozyme, Novo Nordisk, Booking, Mercadolibre & Datadog
Novo Nordisk ($NVO) • By Quality Stocks • 2026-11-09
$NVO: Going against the current
Novo Nordisk ($NVO) • By TQI Capital • 2026-08-12
Can Novo's Perception Get Any Worse?
Novo Nordisk ($NVO) • By Rene Sellmann • 2026-10-02
Earnings Review: AMD & Novo Nordisk
Novo Nordisk ($NVO) • By Rebound Capital • 2025-08-06
The Peptide Fortress: A Deep Dive into Novo Nordisk’s 100-Year Head Start
Novo Nordisk ($NVO) • By CompoundingAlpha • 2026-04-06
$Nvo: Novo Nordisk
Novo Nordisk ($NVO) • By TQI Capital • 2026-01-26
$NVO: Novo Nordisk: When “Cheap” Isn’t Safe
Novo Nordisk ($NVO) • By TQI Capital • 2026-02-05
Novo Nordisk: The most exciting pharma company in the world is misunderstood and its growth engine is ready to roar back to life
Novo Nordisk ($NVO) • By Crack The Market • 2025-05-12
Stock of the Week: Novo Nordisk - A Possible Inflection Point, Powered by Oral Therapies
Novo Nordisk ($NVO) • By Quality Stocks • 2026-01-15
Novo Nordisk ($NVO): A Quality Investing Deep Dive into the GLP-1 Leader's Long-Term Potential and Risks
Novo Nordisk ($NVO) • By Compound & Fire • 2025-11-18
Novo Nordisk, Miracle Drug Creator?
Novo Nordisk ($NVO) • By Quality Stocks • 2024-01-27
Eli Lilly vs Novo Nordisk: a Stock Duel
Novo Nordisk ($NVO) • By Quality Stocks • 2024-10-13
Stock of the Week: Novo Nordisk
Novo Nordisk ($NVO) • By Quality Stocks • 2025-02-13
Stock of the Week - Novo Nordisk: A Fall from Grace Hiding Untapped Opportunities?
Novo Nordisk ($NVO) • By Quality Stocks • 2025-08-12
Novo Nordisk - 9 years later
Novo Nordisk ($NVO) • By Value and Opportunity • 2025-08-01